China Clinical Trial for Medical Devices & IVDs
China has rapidly transformed from a secondary research market into a global leader in clinical development. In 2024 alone, over 4,900 clinical trials were conducted, reflecting a 13.9% year-over-year increase. With sweeping regulatory reform, increasing global data harmonization, and accelerated clinical trial approvals, China has become a strategic destination for global clinical studies, not only for pharmaceuticals, but critically for medical devices and in vitro diagnostics (IVDs).
Cisema is a specialized Contract Research Organization (CRO) and regulatory consulting partner, supporting medical device and IVD manufacturers through the entire China clinical trial and product registration process, including the various processes and documentation required for regulatory compliance. From study design, protocol development, and execution to regulatory submission and final National Medical Product Administration (NMPA) approval, we provide a fully integrated pathway to market success.
Why Global Sponsors Choose China for Their Medical Device & IVD Clinical Trial
Unprecedented Scale and Opportunity
- Over 4,900* clinical trials were conducted in 2024 (*including pharmaceuticals trials)
- 51.8% focused on innovative products
- Patient populations remain relatively treatment-naive
- Strong growth in multi-country and global clinical studies
- China’s extensive network of hospitals, particularly Class III Grade A hospitals in major cities, serves as primary sites for clinical trials, providing robust infrastructure and a competitive landscape for clinical research.
Regulatory Transformation Under the NMPA
- 60-working-day silent approval mechanism for clinical trial applications
- Proposed 30-day review timeline for priority products
- Transition from site accreditation to site registration
- ICH harmonization for global data accuracy and acceptance.
Cost and Speed Advantages
- Significant cost savings and faster timelines compared to many other countries, supported by a strong clinical research infrastructure
- Expanding CRO ecosystem providing full-service support
- Access to an extensive and treatment-naive patient pool
- Backed by the Chinese government through policies promoting Innovation, quality control and new guidance to streamline the clinical trial process.
Why Cisema is Your CRO Partner of Choice
Cisema offers more than operational support, we add strategic value at every stage of your clinical trial and regulatory journey. As both a Contract Research Organization (CRO) and a regulatory consulting specialist, we support manufacturers of medical devices and IVDs from study design, trial execution, and data management all the way through to final National Medical Product Administration (NMPA) approval and product registration.
Unlike traditional CROs focused solely on clinical trials, Cisema ensures that the trial protocol, endpoints, and data collection methods are aligned from the outset with NMPA marketing authorization requirements and supplementary notice expectations. Our integrated approach eliminates costly handovers and guarantees continuity, efficiency, and full compliance.
This seamless transition from clinical trial execution to regulatory success makes Cisema your single-source partner in China.
Cisema’s Clinical Trial Services for Medical Devices & IVDs
Strategic Planning & Protocol Development
We shape each clinical trial strategy around your product’s risk classification, intended use, and technical documentation.
Our solutions include:
Regulatory Submissions & IEC Coordination
We manage:
Clinical Site & Investigator Selection
We recommend high-quality clinical trial sites and investigators based on product type, ensuring the selection of leading hospitals and experienced researchers for optimal trial outcomes:
Our solutions include:
Trial Execution & Oversight
We ensure everything runs smoothly with:
Our solutions include:
Data Management & Statistical Analysis
We deliver full control over data accuracy through:
Our solutions include:
Reporting & Study Close-Out
We prepare:
Market Access & Commercial Strategy
Following product approval, we support your transition to commercialization by guiding pricing, reimbursement, and stakeholder engagement strategies. Our market access experts help you define and communicate your product’s value within the local healthcare landscape.
Our solutions include:
Post-Market Clinical Support & Real World Evidence
We support the full post-approval phase, helping you maintain regulatory compliance and generate robust evidence to demonstrate product performance, safety, and potential for label expansion.
Our solutions include:
Our 5-Step Process for China Medical Device Trial Success
Step 1: Build a Dedicated Project Team
Create a customized Clinical Trial Project Development (CTPD) plan to optimize costs, timelines, and overall project efficiency.
Step 2: Build a Dedicated Project Team
Establish a professional team comprising a Project Supervisor, client-side Project Manager, site Project Manager, CRA, and medical experts.
Step 3: Build a Dedicated Project Team
Hold regular meetings between Cisema’s team and the client’s team to maintain alignment and address project issues promptly.
Step 4: Conduct a Protocol Discussion Panel
Organize a Protocol Discussion Panel involving the Principal Investigator (PI) and client to review and align on the clinical trial protocol.
Step 5: Support the NMPA Review Process
Manage clinical data collection and report preparation while supporting the client throughout the NMPA technical review and supplementary process.
China Medical Device CRO FAQs
Not necessarily. Devices on the NMPA Exemption Catalogue or supported by sufficient existing clinical evaluation may bypass local clinical trials. Cisema can assess your product and evidence to identify the leanest pathway.
Yes, provided it meets NMPA’s overseas clinical data acceptance guidelines. We evaluate your global dataset for ethnic differences and GCP compliance to determine if supplemental local data is needed.
CROs with an on the ground presence in China and global perspective provide the regulatory knowledge, hospital and investigator network, and on-the-ground coordination needed to manage China-specific clinical trial requirements. Cisema combines these capabilities with international regulatory expertise.
Yes. We match your medical device with suitable hospitals and investigators based on your study requirements, and target patient population. We can also coordinate site start-up, contracting, training, and ongoing communication throughout the clinical trial.
Timelines vary based on enrollment targets, site count, and ethics board approvals. Cisema can assess your project and identify key milestones, dependencies, and potential timeline risks before the study begins.
Pricing depends on trial scope, site volume,patient cohort size, and data management needs. We provide transparent, itemized proposals tailored to your project milestones.
Clinical Research in China: A Strategic Advantage
Start Your China Clinical Trial with Cisema
Whether you're validating a high-risk IVD or conducting a pivotal Class III medical device trial, Cisema provides the strategic guidance and local support needed for success. Our integrated approach, from study design, execution, and data management to full regulatory submission, ensures your clinical trial is accepted, compliant, and ready for market.
Get in Touch with Our China Clinical Trial Experts
Cisema’s clinical trial and regulatory specialists are ready to guide your medical device or IVD through every step in China. Let us help you design, execute, and submit a successful clinical trial that meets NMPA requirements, ensures data accuracy, and accelerates your product’s market entry.
